

For immediate release

01 July 2024



**ALLIANCE PHARMA PLC**  
("Alliance" or the "Company")

### **Total Voting Rights**

**Alliance Pharma plc** (AIM: APH), the international healthcare group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

As at 30 June 2024 the Company's issued share capital consists of 540,565,539 Ordinary Shares of 1p each.

The total number of voting rights in the Company is 540,565,539 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

### **For further information:**

**Alliance Pharma plc**

Head of Investor Relations: Cora McCallum  
[ir@allianceph.com](mailto:ir@allianceph.com)

+ 44 (0)1249 466966  
+ 44 (0)1249 705168

**Burson Buchanan**

Mark Court / Sophie Wills  
[alliancepharma@buchanan.uk.com](mailto:alliancepharma@buchanan.uk.com)

+ 44 (0)20 7466 5000

**Deutsche Numis (Nominated Adviser and Joint Broker)**

Freddie Barnfield / Duncan Monteith / Sher Shah

+ 44 (0)20 7260 1000

**Investec Bank plc (Joint Broker)**

Patrick Robb / Maria Gomez de Olea

+ 44 (0)20 7597 5970

### **About Alliance**

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: [www.alliancepharmaceuticals.com](http://www.alliancepharmaceuticals.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

